Biochemical indicators of blood serum and features of toxoplasmosis clinical manifestations in dogs
Journal of Biometry Studies · 2023
DOI: 10.29329/jofbs.2023.501.03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biometry Studies, 2023. Verfasst von Volodymyr Kusturov und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Traditional approaches to the diagnosis of toxoplasmosis include etiological, immunological and imaging methods. However, veterinarians lack clinical markers that would be the basis for testing for toxoplasmosis. Authors found that for toxoplasmosis, the serum of dogs has a high content of ALT enzymes in 68.5% and AST in 91% of cases. In 39.7%, toxoplasmosis is associated with skin lesions and in 20.5% with lesions of the nervous system. In this article, authors summarize that in circumstances of existance of skin and nervous system lesions and a high content of AlAT and AsAT enzymes (according to the results of biochemical tests of blood serum) are found in dogs in veterinary clinics, - a test for toxoplasmosis is recommended. The obtained data create a basis for further research in understanding the pathogenetic mechanisms of toxoplasmosis clinical signs in dogs development. These studies will contribute to a better understanding of the epidemiology, prevention and control of toxoplasmosis.
Zitieren
APA
Kusturov, V., Broshkov, M., & Naida, V. (2023). Biochemical indicators of blood serum and features of toxoplasmosis clinical manifestations in dogs. Journal of Biometry Studies. https://doi.org/10.29329/jofbs.2023.501.03
Vancouver
Kusturov V, Broshkov M, Naida V. Biochemical indicators of blood serum and features of toxoplasmosis clinical manifestations in dogs. Journal of Biometry Studies. 2023. doi:10.29329/jofbs.2023.501.03
BibTeX
@article{Kusturov2023,
author = {Kusturov, Volodymyr and Broshkov, Mykhailo and Naida, Vasyl},
title = {Biochemical indicators of blood serum and features of toxoplasmosis clinical manifestations in dogs},
journal = {Journal of Biometry Studies},
year = {2023},
doi = {10.29329/jofbs.2023.501.03}
}
EUVIMED